Table 4.
Incidence, severity, involvement, and morphology of acne events (up to the week 52 cutoff date)
| Parameter | UPA 15 mg + TCS, N = 133a | UPA 30 mg + TCS, N = 136a |
|---|---|---|
| Patients with acne events, n (%) | 23 (17.3) | 44 (32.4) |
| Severity | ||
| Mild | 11 (8.3) | 27 (19.9) |
| Moderate | 12 (9.0) | 17 (12.5) |
| Severe | 0 | 0 |
| Sex, n/N (%) | ||
| Male | 17/102 (16.7) | 31/107 (29.0) |
| Mild | 8/17 (47.1) | 17/31 (54.8) |
| Moderate | 9/17 (52.9) | 14/31 (45.2) |
| Female | 6/31 (19.4) | 13/29 (44.8) |
| Mild | 3/6 (50.0) | 10/13 (76.9) |
| Moderate | 3/6 (50.0) | 3/13 (23.1) |
| Age, n/N (%) | ||
| < 18 years | 3/12 (25.0) | 4/12 (33.3) |
| 18 to < 30 years | 9/33 (27.3) | 17/39 (43.6) |
| 30 to < 40 years | 6/31 (19.4) | 9/31 (29.0) |
| 40 to < 65 years | 5/56 (8.9) | 14/53 (26.4) |
| ≥ 65 years | 0/1 (0) | 0/1 (0) |
| Acne leading to discontinuation of study drug | 0 | 0 |
| Areas of acne involvement, n (%) | ||
| Face | 20 (87.0) | 43 (97.7) |
| Trunk | 5 (21.7) | 11 (25.0) |
| Extremities | 2 (8.7) | 4 (9.1) |
| Morphology for acne, n (%) | ||
| Inflammatory papules | 20 (87.0) | 39 (88.6) |
| Pustules | 10 (43.5) | 25 (56.8) |
| Comedones | 8 (34.8) | 18 (40.9) |
| Inflammatory nodules and cysts | 2 (8.7) | 1 (2.3) |
| Scarring | 1 (4.3) | 1 (2.3) |
TCS topical corticosteroids, UPA upadacitinib
aIncludes patients who received placebo (UPA 15 mg, n = 42; UPA 30 mg, n = 45) during the double-blind period and switched to UPA during the blinded extension period